Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Phase 1

Active, not recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Busulfan 3.2 mg/kg/day
Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte globulin (ATG)
Drug: Busulfan 0.8 mg/kg
Procedure: Allogeneic hematopoietic cell transplantation (Allo-HCT)

First Posted Date: 2019-09-23

Last Posted Date: 2024-06-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT04098393

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)

Phase 2

Active, not recruiting

Conditions: Cancer Pain

Interventions: Procedure: Massage
Procedure: Acupuncture

First Posted Date: 2019-09-19

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 300

Registration Number: NCT04095234

Locations: 🇺🇸
Baptist Alliance MCI, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 5 locations

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Phase 1

Active, not recruiting

Conditions: Desmoplastic Small Round Cell Tumor
Rhabdomyosarcoma

Interventions: Drug: Prexasertib
Drug: Irinotecan

First Posted Date: 2019-09-19

Last Posted Date: 2024-10-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT04095221

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Phase 2

Recruiting

Conditions: Invasive Ductal Carcinoma, Breast
DCIS Grade 2
DCIS
Breast Cancer
Invasive Ductal Breast Carcinoma
DCIS Grade 1

Interventions: Radiation: Accelerated Partial Breast Irradiation

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 280

Registration Number: NCT04084730

Locations: 🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸
Baptist Alliance Miami Cancer Institute, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 6 locations

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma

Interventions: Drug: Talazoparib
Drug: Avelumab

First Posted Date: 2019-08-28

Last Posted Date: 2024-12-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT04068831

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Diagnostic Test: F-Var3 PET/CT
Other: Blood draw

First Posted Date: 2019-08-13

Last Posted Date: 2020-09-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT04054986

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

Active, not recruiting

Conditions: Adnexal Mass
Ovarian Cancer

First Posted Date: 2019-08-09

Last Posted Date: 2024-02-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT04051502

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

and more 4 locations

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Phase 2

Active, not recruiting

Conditions: Pituitary Tumor
Pituitary
Pituitary Carcinoma
Pituitary Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2019-08-02

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT04042753

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 5 locations

Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma

Phase 1

Completed

Conditions: Pleural Mesothelioma
Wilms Tumor
Mesothelioma

Interventions: Biological: Galinpepimut-S
Drug: Nivolumab
Biological: Sargramostim

First Posted Date: 2019-07-31

Last Posted Date: 2024-11-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04040231

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States

and more 3 locations

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Active, not recruiting

Conditions: Prostate Cancer
Prostate Cancer Metastatic
Prostate Neoplasm
Prostate Adenocarcinoma
Metastatic Prostate Cancer

Interventions: Drug: 18F-DCFPyL-iPSMA
Drug: 68Ga-HBED-iPSMA
Diagnostic Test: PET/CT scan

First Posted Date: 2019-07-23

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT04030338

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy